Patients are taking targeted "smart drugs" with milder side effects than chemotherapy over long periods at considerable expense, but when they can stop taking those drugs is unclear. Clinical trials are under way involving patients with chronic myelogenous leukemia whose cancer is either undetectable or has not grown for two or three years to see what happens when they stop taking Novartis' Gleevec.

Related Summaries